- Company
- Is the heyday of domestic flu vaccines coming to an end?
- by Moon, sung-ho Sep 10, 2024 05:48am
- Competition among pharmaceutical and biotech companies with influenza (flu) vaccines is intensifying more than ever. As more and more companies, including global pharmaceutical companies, are seeking to supply vaccines on-site, and specialized vaccines are being launched for each age group, the competition is expected to be unprecedented thi
- Company
- Livtencity's introduction raises expectations in the field
- by Hwang, Byung-woo Sep 10, 2024 05:47am
- The introduction of Livtencity (maribavir), a drug that can be prescribed to manage infections in transplant patients following the use of existing treatments, has been met with positive reviews in the field due to a lack of treatment options. Although the actual number of patients who will be prescribed the drug is limited, the drug is expec
- Company
- Eliquis generics to enter and reshape DOAC mkt in SEP
- by Moon, Sung-ho Sep 10, 2024 05:47am
- From this month (September), numerous generic drugs will be released in the direct-acting oral anticoagulant (DOAC) market. Following Bayer's Xarelto (rivaroxaban), Pfizer and BMS's Eliquis (apixaban) is also facing its patent expiry. According to industry sources on the 26th, the Ministry of Health and Welfare recently prepared a notic
- Company
- Hugel hosts Train-The-Trainer seminar for global medical aes
- by Kwon Sung-Yong Sep 9, 2024 09:45am
- Hugel Inc., a leading global medical aesthetics company, said on Monday it hosted the Train-The-Trainer program at the end of August with medical experts from overseas to improve their knowledge and practices of skin rejuvenation. Some 20 medical practitioners from nine countries, including the US, Australia, Canada, China, Taiwan, Japan, Ind
- Company
- 'Vabysmo' likely to receive approval for third indication
- by Eo, Yun-Ho Sep 9, 2024 05:49am
- 'Vabysmo,' the first bispecific antibody for the treatment of ophthalmologic disease, is under review for expanded indication for retinal vein occlusion (RVO) in South Korea. According to industry sources, Roche Korea has applied for expanded approval of Vabysmo (faricimab) from the Ministry of Food and Drug Safety (MFDS). The drug receiv
- Policy
- MFDS announces EUA application of new COVID-19 vaccine
- by Lee, Hye-Kyung Sep 9, 2024 05:49am
- An emergency use authorization process is in progress for new COVID-19 vaccines so that the disease control authorities can inoculate using the vaccines in October. On the 6th, the Ministry of Food and Drug Safety announced an application for emergency use approval of the ‘JN.1 variant-response recombinant protein vaccine for the prevent
- Company
- Jassen’s Balversa can be prescribed in general hospitals
- by Eo, Yun-Ho Sep 9, 2024 05:49am
- The new bladder cancer drug Balversa may now be prescribed in general hospitals in Korea. According to industry sources, Janssen Korea’s FGFR-inhibiting urothelial carcinoma (bladder cancer) drug Balversa (erdafitinib) has recently passed the drug committees (DCs) of tertiary hospitals including Seoul St. Mary's Hospital, Seoul Asan Medi
- Company
- Vonjo receives orphan drug designation in Korea
- by Eo, Yun-Ho Sep 6, 2024 05:48am
- The oral myelofibrosis drug Vonjo has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety announced so on the 3rd through an orphan drug designation. Specifically, the drug is indicated for ‘adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythem
- InterView
- "New targeted therapies for bile duct cancer are in need"
- by Son, Hyung-Min Sep 6, 2024 05:48am
- "Recently, as many companies have conducted various studies in the field of cholangiocarcinoma, effective drugs like Tibsovo have become available in the market. Although the development of targeted therapy for cholangiocarcinoma was highly possible, like lung cancer, studies and investments have been insufficient until now. We are seeing po
- Company
- SGLI2i and dulaglutide similar in reducing dementia risk
- by Hwang, Byung-woo Sep 6, 2024 05:48am
- With interest in the dementia prevention effect of Type 2 diabetes medications such as SGLT-2 inhibitors and GLP-1 RAs rising, a study has been published in Korea on the relative prevention effect between the two medications. On the 3rd, Sungkyunkwan University College of Pharmacy Professor Ju-young Shin’s research team (First author: B
